Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer

ISIdE is an European, multicentric study that aims to assess the efficacy of Sacituzumab Govitecan (SG) in locally advanced or metastatic triple-negative breast cancer where the disease has progressed despite chemotherapy or within 6 months after the end of curative treatments in order to: 1. evaluate the treatment efficacy in less pretreated patients. 2. identify biomarkers that could predict response or resistance to the drug.

Trial Details

NCT ID
NCT05552001
Phase
PHASE3
Sponsor
UNICANCER
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Sacituzumab govitecan
Locations (sample)
  • Villejuif, France|48.7939,2.35992

Key Eligibility Criteria

  • Patient must have signed a written informed consent prior to any trial specific procedures;
  • Note: When the patient is unable to write to give his written consent, a trusted person of their choice, independent from the investigator or the s…
  • Male or female ≥ 18 years of age;
  • Patients with pathologically documented locally advanced inoperable or metastatic triple negative breast cancer (mTNBC) whose disease has progresse…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →